Inappropriate Grading of Adverse Events in Cancer Clinical Trials

To the Editor Consideration of toxic effects is a critical part of cancer treatment. Therefore, the grading and reporting of all grades of adverse events, especially high-grade adverse events, must be standardized to allow for consistency and comparison across trials. The Common Terminology Criteria for Adverse Events (CTCAE) has been widely used for reporting of adverse events in oncology journals and at meetings.¹